Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 183 clinical trials
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

that has come back (relapsed) or has not responded to treatment (refractory). Panobinostat may stop or slow multiple myeloma by blocking the growth of new blood vessels necessary for cancer growth

  • 0 views
  • 15 Dec, 2021
  • 1 location
  • 2 views
  • 04 Oct, 2022
  • 5 locations
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Pembrolizumab is an antibody-drug that stimulates body's natural

  • 0 views
  • 05 Jul, 2022
  • 1 location
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and

  • 0 views
  • 09 Apr, 2023
  • 13 locations
Rituximab and Pegfilgrastim in Treating Patients With Non-Hodgkin's Lymphoma

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and

cancer
monoclonal antibodies
rituximab
  • 46 views
  • 07 Nov, 2020
  • 1 location
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial (AB-LATE02)

recurrence rate and accumulating evidence for a metastatic mechanism encourages exploring adjuvant/neoadjuvant strategies targeting tumor growth and metastatic escape in the context of percutaneous thermal

platelet count
renal function
measurable disease
neutrophil count
  • 0 views
  • 04 Oct, 2022
  • 17 locations
Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen

to infections and may slow tumor growth. It is not yet known how well rintatolimod, aspirin, and interferon-alpha 2b work in treating patients with prostate cancer undergoing surgery.

lipase
tumor cells
prostatectomy
biopsy of prostate
neutrophil count
  • 0 views
  • 27 Oct, 2022
  • 1 location
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent Platinum-resistant Epithelial Ovarian Cancer

-resistant or refractory ovarian cancer, effective treatment options are limited and the prognosis is very poor. Angiogenesis is essential for tumor growth and metastasis, and VEGF/VEGF receptor(VEGFR

fallopian tube
recurrent ovarian cancer
doxorubicin
topotecan
ovarian epithelial carcinoma
  • 5 views
  • 03 Dec, 2021
  • 1 location
A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial Carcinoma

come back. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs such as everolimus and letrozole have been shown to be effective at stopping tumor

ct scan
carcinoma
neutrophil count
lee011
hysterectomy
  • 80 views
  • 18 Oct, 2022
  • 2 locations
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression (GLIOSTAR)

tissues from undesired toxicity. Preclinical experiments with L19TNF have demonstrated tumor growth retardation in various mouse tumor models including models of glioma.

measurable disease
primary brain tumors
lomustine
MRI
  • 0 views
  • 16 May, 2022
  • 1 location